Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation

JCO Precis Oncol. 2021 Apr 19:5:PO.20.00486. doi: 10.1200/PO.20.00486. eCollection 2021.

Authors

Marianne Spengler¹, Megan Wheelden¹, Heath B Mackley², Joseph J Drabick¹

Affiliations

¹ Department of Hematology/Oncology, Penn State Milton S. Hershey Medical Center, Hershey, PA.
² Department of Radiation Oncology, Geisinger Medical Center, Danville, PA.

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Esthesioneuroblastoma, Olfactory / drug therapy*
Esthesioneuroblastoma, Olfactory / genetics
Esthesioneuroblastoma, Olfactory / secondary
Female
Fumarate Hydratase / genetics
Humans
Indazoles / therapeutic use*
Mutation
Nasal Cavity*
Neoplasm Recurrence, Local / drug therapy*
Nose Neoplasms / drug therapy*
Nose Neoplasms / genetics
Nose Neoplasms / pathology
Pyrimidines / therapeutic use*
Remission Induction
Retreatment
Sulfonamides / therapeutic use*
Time Factors

Substances

Indazoles
Pyrimidines
Sulfonamides
pazopanib
Fumarate Hydratase